Wei Han1, Shraddha Sapkota2, Richard Camicioli2,3, Roger A Dixon2,4, Liang Li1. 1. Department of Chemistry, University of Alberta, Edmonton, Alberta, Canada. 2. Neuroscience and Mental Health Institute, University of Alberta, Edmonton, Alberta, Canada. 3. Department of Medicine (Neurology), University of Alberta, Edmonton, Alberta, Canada. 4. Department of Psychology, University of Alberta, Edmonton, Alberta, Canada.
Abstract
OBJECTIVE: To profile the amine/phenol submetabolome to determine potential metabolite biomarkers associated with Parkinson's disease (PD) and PD with incipient dementia. METHODS: At baseline of a 3-wave (18-month intervals) longitudinal study, serum samples were collected from 42 healthy controls and 43 PD patients. By wave 3 (year 3), 16 PD patients were diagnosed with dementia and were classified as PD with incipient dementia at baseline. Metabolomic profiling using dansylation isotope labeling liquid chromatography mass spectrometry was conducted to compare controls with the full PD, PD with no dementia, and PD with incipient dementia groups. RESULTS: Metabolomic analyses detected 719 common metabolites in 80% of the samples. Some were significantly altered in pairwise comparison of different groups (fold change of >1.2 or <0.83 with q < 0.05). We discriminated PD and controls by using a 5-metabolite panel, vanillic acid, 3-hydroxykynurenine, isoleucyl-alanine, 5-acetylamino-6-amino-3-methyluracil, and theophylline. The receiver operating characteristic curve produced an area-under-the-curve value of 0.955 with 87.5% sensitivity and 93.0% specificity. In comparing PD with no dementia with PD with incipient dementia, we used an 8-metabolite panel, His-Asn-Asp-Ser, 3,4-dihydroxyphenylacetone, desaminotyrosine, hydroxy-isoleucine, alanyl-alanine, putrescine [-2H], purine [+O] and its riboside. This produced an area-under-the-curve value of 0.862 with 80.0% sensitivity and 77.0% specificity. CONCLUSIONS: The significantly altered metabolites can be used to differentiate (1) PD patients from healthy controls with high accuracy and (2) the stable PD with no dementia group from those with incipient dementia. Following further validation in larger cohorts, these metabolites could be used for both discrimination and establishing prognosis in PD.
OBJECTIVE: To profile the amine/phenolsubmetabolome to determine potential metabolite biomarkers associated with Parkinson's disease (PD) and PD with incipient dementia. METHODS: At baseline of a 3-wave (18-month intervals) longitudinal study, serum samples were collected from 42 healthy controls and 43 PDpatients. By wave 3 (year 3), 16 PDpatients were diagnosed with dementia and were classified as PD with incipient dementia at baseline. Metabolomic profiling using dansylation isotope labeling liquid chromatography mass spectrometry was conducted to compare controls with the full PD, PD with no dementia, and PD with incipient dementia groups. RESULTS: Metabolomic analyses detected 719 common metabolites in 80% of the samples. Some were significantly altered in pairwise comparison of different groups (fold change of >1.2 or <0.83 with q < 0.05). We discriminated PD and controls by using a 5-metabolite panel, vanillic acid, 3-hydroxykynurenine, isoleucyl-alanine, 5-acetylamino-6-amino-3-methyluracil, and theophylline. The receiver operating characteristic curve produced an area-under-the-curve value of 0.955 with 87.5% sensitivity and 93.0% specificity. In comparing PD with no dementia with PD with incipient dementia, we used an 8-metabolite panel, His-Asn-Asp-Ser, 3,4-dihydroxyphenylacetone, desaminotyrosine, hydroxy-isoleucine, alanyl-alanine, putrescine [-2H], purine [+O] and its riboside. This produced an area-under-the-curve value of 0.862 with 80.0% sensitivity and 77.0% specificity. CONCLUSIONS: The significantly altered metabolites can be used to differentiate (1) PDpatients from healthy controls with high accuracy and (2) the stable PD with no dementia group from those with incipient dementia. Following further validation in larger cohorts, these metabolites could be used for both discrimination and establishing prognosis in PD.
Authors: Michael A Schwarzschild; Kui Xu; Emin Oztas; Jacobus P Petzer; Kay Castagnoli; Neal Castagnoli; Jiang-Fan Chen Journal: Neurology Date: 2003-12-09 Impact factor: 9.910
Authors: Edward J Newman; Kieran Breen; Jim Patterson; Donald M Hadley; Katherine A Grosset; Donald G Grosset Journal: Mov Disord Date: 2009-12-15 Impact factor: 10.338
Authors: David S Wishart; Dan Tzur; Craig Knox; Roman Eisner; An Chi Guo; Nelson Young; Dean Cheng; Kevin Jewell; David Arndt; Summit Sawhney; Chris Fung; Lisa Nikolai; Mike Lewis; Marie-Aude Coutouly; Ian Forsythe; Peter Tang; Savita Shrivastava; Kevin Jeroncic; Paul Stothard; Godwin Amegbey; David Block; David D Hau; James Wagner; Jessica Miniaci; Melisa Clements; Mulu Gebremedhin; Natalie Guo; Ying Zhang; Gavin E Duggan; Glen D Macinnis; Alim M Weljie; Reza Dowlatabadi; Fiona Bamforth; Derrick Clive; Russ Greiner; Liang Li; Tom Marrie; Brian D Sykes; Hans J Vogel; Lori Querengesser Journal: Nucleic Acids Res Date: 2007-01 Impact factor: 16.971
Authors: Fatema Bhinderwala; Shulei Lei; Jade Woods; Jordan Rose; Darrell D Marshall; Eli Riekeberg; Aline De Lima Leite; Martha Morton; Eric D Dodds; Rodrigo Franco; Robert Powers Journal: Methods Mol Biol Date: 2019
Authors: Nicholas J Ashton; Abdul Hye; Anto P Rajkumar; Antoine Leuzy; Stuart Snowden; Marc Suárez-Calvet; Thomas K Karikari; Michael Schöll; Renaud La Joie; Gil D Rabinovici; Kina Höglund; Clive Ballard; Tibor Hortobágyi; Per Svenningsson; Kaj Blennow; Henrik Zetterberg; Dag Aarsland Journal: Nat Rev Neurol Date: 2020-04-22 Impact factor: 42.937
Authors: Hutan Ashrafian; Viknesh Sounderajah; Robert Glen; Timothy Ebbels; Benjamin J Blaise; Dipak Kalra; Kim Kultima; Ola Spjuth; Leonardo Tenori; Reza M Salek; Namrata Kale; Kenneth Haug; Daniel Schober; Philippe Rocca-Serra; Claire O'Donovan; Christoph Steinbeck; Isaac Cano; Pedro de Atauri; Marta Cascante Journal: Med Princ Pract Date: 2020-12-03 Impact factor: 2.132
Authors: Caroline Ballet; Mário S P Correia; Louis P Conway; Theresa L Locher; Laura C Lehmann; Neeraj Garg; Miroslav Vujasinovic; Sebastian Deindl; J-Matthias Löhr; Daniel Globisch Journal: Chem Sci Date: 2018-06-28 Impact factor: 9.825